A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 20, 2014

BMS’s Attachment Inhibitor Shows Promise

CROI 2014A promising trial of Bristol-Myers Squibb’s investigational attachment inhibitor BMS-663068 raises hope of the introduction of a new antiretroviral drug class, which would especially benefit those with multidrug resistance, aidsmap reports. The randomized, controlled Phase IIb trial evaluated the safety and efficacy of BMS-663068 in 253 treatment-experienced people with HIV who had a viral load of at least 1,000 and a CD4 count above 50, and about half of whom had resistance to at least one ARV drug class. Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The study participants randomly received one of five drug regimens that all contained Viread (tenofovir) and Isentress (raltegravir), plus: either BMS-663068 at 400 milligrams or 800 mg twice a day, or 600 mg or 1,200 mg once a day; or (as a control) ritonavir-boosted Reyataz (atazanavir).

After 24 weeks, the treatment arms containing BMS-663068 were similar in efficacy, with a range of 69 to 80 percent of participants achieving an undetectable viral load. This was compared with 75 percent who did so in the control group. The groups all experienced similar increases in CD4 levels.

BMS-663068 proved generally well tolerated regardless of the dose. There were no indications of safety problems.

To read the BMS press release, click here.

To read the aidsmap story, click here.

Search: BMS-663068, Bristol-Myers Squibb, BMS, drug resistance, Viread, tenofovir, Isentress, raltegravir, Reyataz, atazanavir, fostemsavir

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.